Furthermore, in some tumor samples we evaluated FSH-R immunolocalization in vascular endothelium in areas adjacent to the tumor lesion (Figure 4C), whereas for the samples with Leydig cell tumors we used a negative control tissue (Figure 4D). This evidence concerns the gene FSHR and Leydig cell tumor.